


## FABPs ligand 6

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-145990  |
| CAS No.:           | 2988135-14-2   |
| Molecular Formula: | C <sub>28</sub> H <sub>27</sub> FN <sub>2</sub> O <sub>3</sub>                                 |
| Molecular Weight:  | 458.52   |
| Target:            | FABP   |
| Pathway:           | Metabolic Enzyme/Protease  |
| Storage:           | 4°C, protect from light<br>* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |



### SOLVENT & SOLUBILITY

|   |  |                          |      |       |           |            |            |
|---|--|--------------------------|------|-------|-----------|------------|------------|
| In Vitro  | DMSO : 125 mg/mL (272.62 mM; Need ultrasonic)  |                          |      |       |           |            |            |
|   | Preparing Stock Solutions  | Solvent<br>Concentration | Mass | 1 mg  | 5 mg      | 10 mg      |            |
|   |  |                          |      | 1 mM  | 2.1809 mL | 10.9046 mL | 21.8093 mL |
|   |  |                          |      | 5 mM  | 0.4362 mL | 2.1809 mL  | 4.3619 mL  |
|   |  |                          |      | 10 mM | 0.2181 mL | 1.0905 mL  | 2.1809 mL  |
| Please refer to the solubility information to select the appropriate solvent. |  |                          |      |       |           |            |            |
| In Vivo   | 1. Add each solvent one by one: 10% DMSO >> 90% corn oil<br>Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution |                          |      |       |           |            |            |

### BIOLOGICAL ACTIVITY

|                           |   |
|---------------------------|---|
| Description               | FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with K <sub>D</sub> values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research <sup>[1]</sup> .  |
| IC <sub>50</sub> & Target | K <sub>D</sub> : 20 nM (FABP7), 874 nM (FABP5) <sup>[1]</sup>   |
| In Vitro                  | FABPs ligand 6 (MF6) rescues mitochondrial function by blocking voltage-dependent anion channel (VDAC)-1-dependent mitochondrial macropore formation induced by psychosine in KG-1C cells, a FABP5- mediated injury <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo                   | MF 6 (1 mg/kg; i.g.; daily for 4 weeks) improves the severity of EAE (experimental autoimmune encephalomyelitis) and attenuates oxidative levels and the inflammatory response <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.                                      |

|                 |  |
|-----------------|--|
| Animal Model:   | 8-10-week-old female C57BMF/6J mice with MOG <sub>35-55</sub> -administered experimental autoimmune encephalomyelitis (EAE) mouse model <sup>[1]</sup> |
| Dosage:         | 1 mg/kg  |
| Administration: | Intragastric administration, daily for 4 weeks   |
| Result:         | Attenuated EAE symptoms, decreased oxidative stress, inhibited astrocyte activation and protected oligodendrocytes.                                    |

## REFERENCES

[1]. Cheng A, et al. A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models. EBioMedicine. 2021 Oct;72:103582.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA